An Open, Single-arm, Phase 1 Study to Evaluate the Safety/Preliminary Effectiveness and Determine the Maximal Tolerated Dose of B7-H3-targeting CAR-T Cell Therapy in Treating Recurrent Glioblastomas
Latest Information Update: 13 Feb 2025
At a glance
- Drugs Anti B7 H3 chimeric antigen receptor T-cell therapy BoYuan RunSheng Pharma (Primary) ; Anti B7 H3 chimeric antigen receptor T-cell therapy BoYuan RunSheng Pharma (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
Most Recent Events
- 09 Feb 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
- 09 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2024 Preliminary findings (n=13) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.